New quarterly report expected Apr 22, 2026. Report will refresh after results.
M
Molina Healthcare, Inc.
MOH · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Rate Reset Is the Whole Bet: Contract Machine Priced for Permanent Damage
The market is treating 2025 as a verdict on Molina's business quality when it is actually a verdict on Medicaid capitation rate timing — the same contracts, the same provider networks, and the same actuarial discipline that generated high-teens ROIC for four years are still in place, just temporarily underwater because rates are locked while costs ran hot. What most investors are missing is that the Florida CMS contract alone embeds more than four dollars of future annual earnings per share in a stock trading at roughly thirty times that embedded number — meaning the recovery optionality is priced near zero even as management just secured one of the largest Medicaid contract wins in the industry's history.
Flowly Score
Apr 16 Close
+31%$148.87
Fair Value
$195.00
48
Below Averageat $148.87
Business Strength6/10
The moat is real — 40 years of state contract relationships, proprietary Medicaid actuarial data, and genuine switching costs on the government customer side — but 2025 proved how brutally thin the margin for error is in a pure spread business when capitation rates lag medical cost inflation by even 150 basis points. Management's disciplined capital allocation and willingness to exit unprofitable contracts earns genuine credit, but you're betting on execution inside a sector that a single federal budget reconciliation can reprice overnight.
Financial Resilience4/10
The earnings-to-cash divergence in 2025 is the loudest warning signal in this entire analysis — positive reported income alongside deeply negative operating cash flow means the accounting profits are not landing in the bank account, and that gap demands an explanation before any recovery thesis gets credit. Layering debt-funded buybacks on top of deteriorating operating cash generation was precisely the wrong capital allocation call at precisely the wrong moment in the cycle.
Growth & Trajectory5/10
The contract machine itself is genuinely impressive — a 90% renewal win rate and the Florida CMS landmark represent durable top-line building blocks — but a business that grew revenue double-digits while earnings fell by two-thirds is running faster to lose more per member, and the 2026 guidance of a further step-down means the earnings trough has not yet been found. The trajectory depends entirely on whether the rate reset thesis resolves in one year or three.
Valuation7/10at $146.03
At a fraction of a turn on revenue and an EV/EBITDA sitting at a multi-year low, the market is pricing extended impairment into a business that earned returns well north of its cost of capital for four consecutive years — that gap between current multiples and normalized earnings power is the entire investment case in one sentence. The catch is that 'normalized' requires a federal political environment that does not materially restructure Medicaid, which is genuinely uncertain in early 2026 in a way it was not in 2022.
Risk3/10
The risk profile here is not diversified cyclicality — it is concentrated, binary political exposure where a single federal legislative session could simultaneously shrink the membership base, cut per-member payment rates, and extend the medical cost overhang, three forces that compound rather than offset. Negative free cash flow entering a period of active federal entitlement reform with debt now at parity with cash reserves is not a comfortable position from which to absorb a policy shock.
The investment case is essentially a mean-reversion thesis on regulated contract economics with a specific catalyst: when Medicaid capitation rates reset through the normal actuarial soundness process, a business with demonstrated high-teens ROIC will be priced at less than ten times normalized earnings. The interaction between valuation and quality here is unusual — this is not a cheap bad business, it is a demonstrably good business experiencing a cyclical spread compression that the market is treating as structural impairment. The spread between current multiples and the five-year ROIC history is wider than any fundamental deterioration in the actual competitive position would justify. Where this business is heading depends on two parallel tracks running at different speeds: the rate restoration track, where state Medicaid agencies rebuild actuarial soundness over one to two contract cycles, and the contract growth track, where Florida alone adds a revenue base larger than many standalone managed care companies. The Marketplace pivot — deliberately accepting enrollment losses in exchange for margin discipline — signals that management understands the difference between revenue that creates value and revenue that destroys it, which is rarer than it sounds in an industry that has historically chased membership growth regardless of profitability. The single biggest risk is not medical cost trends or actuarial mispricing — those are cyclical and recoverable. The existential risk is federal Medicaid restructuring into block grants or work requirement-triggered membership attrition at a scale that permanently reduces the addressable population. Active legislative proposals in early 2026 are not hypothetical; they are drafts moving through committees, and Molina has no revenue outside government programs to serve as a cushion. If federal matching rates are cut materially, the recovery thesis does not merely slow — the normalized earnings base itself shrinks, and every multiple-based valuation becomes an anchor attached to a smaller ship.